So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature

Ruth Gabriela Herrera Gómez; Delfyne Hastir; Aikaterini Liapi; Ana Dolcan; Fernanda G Herrera; Patrice Mathevet; Apostolos Sarivalasis

doi:10.1159/000520429

So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature

Case Rep Oncol. 2021 Dec 20;14(3):1792-1798. doi: 10.1159/000520429. eCollection 2021 Sep-Dec.

Authors

Ruth Gabriela Herrera Gómez¹, Delfyne Hastir², Aikaterini Liapi¹, Ana Dolcan¹, Fernanda G Herrera³, Patrice Mathevet⁴, Apostolos Sarivalasis¹

Affiliations

¹ Oncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
² Pathology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
³ Radiation Oncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
⁴ Department of Obstetrics and Gynecology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Abstract

Serous carcinoma of the uterine cervix (SCUC) is now believed to be a morphological variant of an HPV-associated endocervical adenocarcinoma or a metastasis from a serous carcinoma of the upper tract. In terms of mutational status as detected by next-generation sequencing (NGS), this controversial entity has not been characterized yet. We describe the case of a patient with a carcinoma categorized as stage IVB SCUC, initially treated with carboplatin, paclitaxel, and bevacizumab, followed by maintenance with bevacizumab. After locoregional progression, radiotherapy was administered. Unfortunately, further progression was observed, and carboplatin was resumed. Considering the presence of a BRCA2 mutation as detected by NGS, treatment with a PARP inhibitor (olaparib) was decided and allowed disease control for 6 months. We believe that BRCA mutation may be systematically searched in patients suffering from carcinomas formerly referred to as SCUC and that targeted treatments should be considered.

Keywords: BRCA mutation; Cervix serous carcinoma; Rare tumors.

Publication types

Case Reports